Cell therapy (Stem-cell derived) · developed by Mesoblast International Sàrl
OTI-010 is an autologous expanded mesenchymal stem cell product, made from multipotent stromal cells harvested from the patient's bone marrow and grown in vitro. When injected back into the patient, the cells may differentiate into mesenchyme-derived cell types and may augment bone marrow engraftment after whole-body irradiation. It is studied in graft versus host disease, leukemia and myelodysplastic syndromes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00081055 | Phase 2 | Graft Versus Host Disease | Withdrawn | MESO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
See MESO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MESO catalysts and pipeline →